Purinergic Signalling: Therapeutic Developments.
Burnstock G. · 2017
Read Purinergic Signalling: Therapeutic Developments. by Burnstock G. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5622197.txt.
Introduction
Burnstock reviews drug progress in purinergic signalling for Frontiers in Pharmacology. The idea that nucleotides signal between cells dates to 1972. It gained ground once receptor subtypes were cloned. Nineteen subtypes now span the P1, P2X, and P2Y families.
Several purinergic drugs already serve patients. Clopidogrel blocks the P2Y12 receptor to prevent clots and stroke. Diquafosol treats dry eye through P2Y2. Adenosine drugs steady fast heart rhythms. A2A blockers look promising for Parkinson's disease. Newer candidates target other receptors. P2X3 blockers are in trials for chronic cough and bladder problems. P2X7 blockers are studied for inflammation and brain disease. Work also spans bone loss, diabetes, epilepsy, and cancer. Readers get a field survey from the scientist who named it, focused on what may reach the clinic.
Catalog record
| CREATOR | Burnstock G. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 381 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |